journal
https://read.qxmd.com/read/36948982/what-s-in-a-number-the-value-of-titers-as-routine-proof-of-immunity-for-medical-students
#1
JOURNAL ARTICLE
Carmen L Charlton, Ashley-Nicole M Bailey, L Alexa Thompson, Jamil N Kanji, Natalie C Marshall
OBJECTIVES: To assess the guideline concordance of medical school requirements for students' proof-of-immunity in the United States (US) and Canada. METHODS: National guidelines for healthcare worker proof-of-immunity to measles, mumps, rubella, and varicella were compared to admission requirements for 62 US and 17 Canadian medical schools. RESULTS: All surveyed schools accepted at least one recommended form of proof-of-immunity, however, contrary to national guidelines, 16% of surveyed US schools asked for a serologic titer, and only 73-79% US schools accepted vaccination as the sole proof-of-immunity...
March 20, 2023: Vaccine
https://read.qxmd.com/read/36948981/the-economic-impact-of-the-introduction-of-universal-rotavirus-vaccination-on-rotavirus-gastroenteritis-related-hospitalisations-in-children-in-ireland
#2
JOURNAL ARTICLE
Aileen Murphy, Ann Kirby, Federica De Blasio
BACKGROUND: Rotavirus gastroenteritis (RVGE), a vaccine preventable disease, remains a common cause of severe gastroenteritis in children globally. Ireland introduced the universal rotavirus vaccination to the national immunisation programme in 2016. In this paper the economic impact on RVGE related hospitalisations amongst children under 5 years is examined. METHODS: Using national data from all Irish public hospitals, an Interrupted Times Series Analysis (ITSA) compares RVGE hospitalisations amongst children under 5 years, pre- and post-vaccine introduction...
March 20, 2023: Vaccine
https://read.qxmd.com/read/36941155/safety-and-immunogenicity-of-multimeric-001-m-001-followed-by-seasonal-quadrivalent-inactivated-influenza-vaccine-in-young-adults-a-randomized-clinical-trial
#3
JOURNAL ARTICLE
Robert L Atmar, David I Bernstein, Patricia Winokur, Sharon E Frey, Laura S Angelo, Christopher Bryant, Tammy Ben-Yedidia, Paul C Roberts, Hana M El Sahly, Wendy A Keitel
BACKGROUND: The continuing evolution of influenza viruses poses a challenge to vaccine prevention, highlighting the need for a universal influenza vaccine. We evaluated the safety and immunogenicity of one such candidate, Multimeric-001 (M-001), when used as a priming vaccine prior to administration of quadrivalent inactivated influenza vaccine (IIV4). METHODS: Healthy adults 18 to 49 years of age were enrolled in a phase 2 randomized, double-blind placebo-controlled trial...
March 18, 2023: Vaccine
https://read.qxmd.com/read/36941154/economic-burden-and-health-related-quality-of-life-among-infants-with-respiratory-syncytial-virus-infection-a-multi-country-prospective-cohort-study-in-europe
#4
JOURNAL ARTICLE
Zhuxin Mao, Xiao Li, Ana Dacosta-Urbieta, Marie-Noëlle Billard, Joanne Wildenbeest, Koos Korsten, Federico Martinón-Torres, Terho Heikkinen, Steve Cunningham, Matthew D Snape, Hannah Robinson, Andrew J Pollard, Maarten Postma, Benoit Dervaux, Niel Hens, Louis Bont, Joke Bilcke, Philippe Beutels
BACKGROUND: Respiratory syncytial virus (RSV) causes a considerable disease burden in young children globally, but reliable estimates of RSV-related costs and health-related quality-of-life (HRQoL) are scarce. This study aimed to evaluate the RSV-associated costs and HRQoL effects in infants and their caregivers in four European countries. METHODS: Healthy term-born infants were recruited at birth and actively followed up in four European countries. Symptomatic infants were systematically tested for RSV...
March 18, 2023: Vaccine
https://read.qxmd.com/read/36935288/cellular-and-humoral-responses-to-an-hiv-dna-prime-by-electroporation-boosted-with-recombinant-vesicular-stomatitis-virus-expressing-hiv-subtype-c-env-in-a-randomized-controlled-clinical-trial
#5
JOURNAL ARTICLE
Gregory J Wilson, Benigno Rodriguez, Shuying Sue Li, Mary Allen, Ian Frank, Erika Rudnicki, Meg Trahey, Spyros Kalams, Drew Hannaman, David K Clarke, Rong Xu, Michael Egan, John Eldridge, Michael Pensiero, Theresa Latham, Guido Ferrari, David C Montefiori, Georgia D Tomaras, Stephen C De Rosa, Jeffrey M Jacobson, Maurine D Miner, Marnie Elizaga
BACKGROUND: HIV subtypes B and C together account for around 60% of HIV-1 cases worldwide. We evaluated the safety and immunogenicity of a subtype B DNA vaccine prime followed by a subtype C viral vector boost. METHODS: Fourteen healthy adults received DNA plasmid encoding HIV-1 subtype B nef/tat/vif and env (n = 11) or placebo (n = 3) intramuscularly (IM) via electroporation (EP) at 0, 1, and 3 months, followed by IM injection of recombinant vesicular stomatitis virus encoding subtype C Env or placebo at 6 and 9 months...
March 17, 2023: Vaccine
https://read.qxmd.com/read/36935287/when-should-a-longer-needle-be-used-for-intramuscular-injection-in-obese-patients-a-combined-analysis-of-new-zealand-data
#6
JOURNAL ARTICLE
Marjan Doppen, Ciléin Kearns, Mark Weatherall, Nethmi Kearns, Peter McIntyre, Thomas Hills, Richard Beasley
AIM: To estimate thresholds for Body Mass Index (BMI) and arm circumference above which a longer needle is needed to ensure intramuscular (IM) delivery of a vaccine in the deltoid muscle at the site recommended by New Zealand (NZ) immunization guidelines. METHODS: A combined analysis of two studies, including 442 adults, with measurements of arm circumference, BMI and skin to deltoid muscle distance (SDMD) at the NZ immunization guideline-recommended IM injection site...
March 17, 2023: Vaccine
https://read.qxmd.com/read/36933984/differential-coverage-for-vaccines-in-the-expanded-program-on-immunization-epi-among-children-in-rural-pakistan
#7
JOURNAL ARTICLE
Shahira Shahid, Sheraz Ahmed, Muhammad Farrukh Qazi, Rafey Ali, Syed Asad Ali, Anita K M Zaidi, Najeeha T Iqbal, Fyezah Jehan, Muhammad Imran Nisar
BACKGROUND: Pakistan has a well-established Expanded Program on Immunization (EPI) however vaccine-preventable diseases still account for high infant and child mortality rates. This study describes the differential vaccine coverage and determinants of vaccine uptake in rural Pakistan. METHODS: From October 2014 to September 2018, we enrolled children younger than 2 years of age from the Matiari Demographic Surveillance System in Sindh, Pakistan. Socio-demographic and vaccination history were collected from all participants...
March 16, 2023: Vaccine
https://read.qxmd.com/read/36933982/the-burden-of-invasive-meningococcal-disease-in-the-netherlands-2011-2020
#8
JOURNAL ARTICLE
Marit Middeldorp, Anneke Steens, Giske Lagerweij, Nina M van Sorge, Wieke Freudenburg-de Graaf, Elisabeth A M Sanders, Hester E de Melker, Mirjam J Knol
INTRODUCTION: Representative information on disease course and outcome of invasive meningococcal disease (IMD) is important because of the shift in meningococcal epidemiology that recently occurred in the Netherlands. With this study, we update earlier research on the burden of IMD in the Netherlands. MATERIAL AND METHODS: We performed a retrospective study using Dutch surveillance data on IMD from July 2011 to May 2020. Clinical information was collected from hospital records...
March 16, 2023: Vaccine
https://read.qxmd.com/read/36933981/changes-in-vaccination-administration-in-japan
#9
JOURNAL ARTICLE
Takashi Nakano
This paper reviews the administration related to vaccination in Japan after the enactment of the Immunization Act in 1948, under which vaccination was implemented mandatory for the public. To enhance the effectiveness of vaccination activities, the government implemented group vaccination, which is convenient for vaccinating recipients all at once. In 1976, Japan established the relief system for health damage after vaccination. While some projects, such as the mass administration of live oral polio vaccine in 1961, achieved excellent results, incidents leading to health damage occurred, such as the diphtheria toxoid immunization incident (1948) and frequent occurrence of aseptic meningitis owing to the measles, mumps, and rubella vaccine (1989)...
March 16, 2023: Vaccine
https://read.qxmd.com/read/36932030/challenges-and-opportunities-in-developing-a-shigella-containing-combination-vaccine-for-children-in-low-and-middle-income-countries-report-of-an-expert-convening
#10
Mark S Riddle, A Louis Bourgeois, Allison Clifford, Suhi Jeon, Birgitte K Giersing, Mark Jit, Marta Tufet Bayona, Jared Ovitt, William P Hausdorff
The gram-negative bacterium Shigella is an enteric pathogen responsible for significant morbidity and mortality due primarily to severe diarrhea and dysentery, mainly among children younger than five years of age living in low- and middle-income countries (LMICs). Long considered a priority target for vaccine development, recent scientific advances have led to a number of promising Shigella vaccine candidates now entering advanced stages of clinical testing. Yet, there is no guarantee that even a highly efficacious Shigella vaccine will be recommended, prioritized, purchased, and widely adopted-especially if it requires additional doses in the immunization schedule and/or visits within the immunization program...
March 15, 2023: Vaccine
https://read.qxmd.com/read/36925423/mediation-and-instrumental-variable-analyses-for-vaccine-induced-antibody-titer-against-influenza-b
#11
JOURNAL ARTICLE
Jui-Hsiang Lin, Yi-Ting Huang, Jih-Chang Yu, Kin-Wei Arnold Chan, Yen-Tsung Huang
OBJECTIVE: Immune correlate analyses for vaccine trials have been applied to investigate associations of vaccine efficacy and surrogate markers such as vaccine-induced antibodies. However, the role of antibody as a surrogate marker in predicting the outcome can vary by time, and surrogate-outcome confounding may have resulted in bias even in randomized trials. We provide a framework for surrogate marker assessment to address the aforementioned issues. STUDY DESIGN AND SETTING: We reanalyzed the vaccine randomized trial for influenza B...
March 14, 2023: Vaccine
https://read.qxmd.com/read/36933985/latent-class-analysis-of-medical-mistrust-and-covid-19-vaccine-hesitancy-among-adults-in-the-united-states-just-prior-to-fda-emergency-use-authorization
#12
JOURNAL ARTICLE
Phoebe A Lamuda, Ariel Azar, Bruce G Taylor, Elizabeth Flanagan Balawajder, Harold A Pollack, John A Schneider
Using a nationally representative household sample, we sought to better understand types of medical mistrust as a driver of COVID-19 vaccine hesitancy. We used survey responses to conduct a latent class analysis to classify respondents into categories and explained this classification as a function of sociodemographic and attitudinal variables using multinomial logistic regression models. We then estimated the probability of respondents agreeing to receive a COVID-19 vaccine conditional on their medical mistrust category...
March 13, 2023: Vaccine
https://read.qxmd.com/read/36907735/editorial-from-guest-editors-for-vaccine-supplement-vaccine-derived-poliovirus-type-2-outbreaks-after-the-cessation-of-use-of-oral-poliovirus-vaccine-type-2_-2016-2021-journal-supplement
#13
EDITORIAL
https://read.qxmd.com/read/36907737/updated-estimate-of-the-annual-direct-medical-cost-of-screening-and-treatment-for-human-papillomavirus-associated-disease-in-the-united-states
#14
JOURNAL ARTICLE
Patrick A Clay, Trevor D Thompson, Lauri E Markowitz, Donatus U Ekwueme, Mona Saraiya, Harrell W Chesson
The annual direct medical cost attributable to human papillomavirus (HPV) in the United States over the period 2004-2007 was estimated at $9.36 billion in 2012 (updated to 2020 dollars). The purpose of this report was to update that estimate to account for the impact of HPV vaccination on HPV-attributable disease, reductions in the frequency of cervical cancer screening, and new data on the cost per case of treating HPV-attributable cancers. Based primarily on data from the literature, we estimated the annual direct medical cost burden as the sum of the costs of cervical cancer screening and follow-up and the cost of treating HPV-attributable cancers, anogenital warts, and recurrent respiratory papillomatosis (RRP)...
March 10, 2023: Vaccine
https://read.qxmd.com/read/36907734/prevalence-of-influenza-specific-vaccination-hesitancy-among-adults-in-the-united-states-2018
#15
JOURNAL ARTICLE
Anup Srivastav, Peng-Jun Lu, Ashley Amaya, Jill A Dever, Marshica Stanley, Jessica L Franks, Paul J Scanlon, Allison M Fisher, Stacie M Greby, Kimberly H Nguyen, Carla L Black
BACKGROUND: The role of vaccine hesitancy on influenza vaccination is not clearly understood. Low influenza vaccination coverage in U.S. adults suggests that a multitude of factors may be responsible for under-vaccination or non-vaccination including vaccine hesitancy. Understanding the role of influenza vaccination hesitancy is important for targeted messaging and intervention to increase influenza vaccine confidence and uptake. The objective of this study was to quantify the prevalence of adult influenza vaccination hesitancy (IVH) and examine association of IVH beliefs with sociodemographic factors and early-season influenza vaccination...
March 10, 2023: Vaccine
https://read.qxmd.com/read/36907733/vaccine-derived-poliovirus-serotype-2-outbreaks-and-response-in-the-democratic-republic-of-the-congo-2017-2021
#16
JOURNAL ARTICLE
Mary M Alleman, Jaume Jorba, Yogolelo Riziki, Elizabeth Henderson, Anicet Mwehu, Lerato Seakamela, Wayne Howard, Albert Kadiobo Mbule, Renee Ntumbannji Nsamba, Kpandja Djawe, Moïse Désiré Yapi, Marcellin Nimpa Mengouo, Nicksy Gumede, Modjirom Ndoutabe, Anfumbom K W Kfutwah, Kamel Senouci, Cara C Burns
Vaccine-derived polioviruses (VDPVs) can emerge from Sabin strain poliovirus serotypes 1, 2, and 3 contained in oral poliovirus vaccine (OPV) after prolonged person-to-person transmission where population vaccination immunity against polioviruses is suboptimal. VDPVs can cause paralysis indistinguishable from wild polioviruses and outbreaks when community circulation ensues. VDPV serotype 2 outbreaks (cVDPV2) have been documented in The Democratic Republic of the Congo (DRC) since 2005. The nine cVDPV2 outbreaks detected during 2005-2012 were geographically-limited and resulted in 73 paralysis cases...
March 10, 2023: Vaccine
https://read.qxmd.com/read/36932031/estimated-covid-19-vaccine-effectiveness-against-seroconversion-from-sars-cov-2-infection-march-october-2021
#17
JOURNAL ARTICLE
Ian D Plumb, Lida M Fette, Ashley H Tjaden, Leora Feldstein, Sharon Saydah, Amina Ahmed, Ruth Link-Gelles, Thomas F Wierzba, Andrea A Berry, DeAnna Friedman-Klabanoff, Moira P Larsen, Michael S Runyon, Lori M Ward, Roberto P Santos, Johnathan Ward, William S Weintraub, Sharon Edelstein, Diane Uschner
BACKGROUND: Monitoring the effectiveness of COVID-19 vaccines against SARS-CoV-2 infections remains important to inform public health responses. Estimation of vaccine effectiveness (VE) against serological evidence of SARS-CoV-2 infection might provide an alternative measure of the benefit of vaccination against infection. METHODS: We estimated mRNA COVID-19 vaccine effectiveness (VE) against development of SARS-CoV-2 anti-nucleocapsid antibodies in March-October 2021, during which the Delta variant became predominant...
March 9, 2023: Vaccine
https://read.qxmd.com/read/36906409/use-of-an-adapted-participatory-learning-and-action-cycle-to-increase-knowledge-and-uptake-of-child-vaccination-in-internally-displaced-persons-camps-ivacs-a-cluster-randomised-controlled-trial
#18
JOURNAL ARTICLE
Andrew J Seal, Hodan Abdullahi Mohamed, Ronald Stokes-Walter, Sadik Mohamed, Amina Mohamed Abdille, Ellyn Yakowenko, Mohamed Sheikh Omar, Mohamed Jelle
BACKGROUND: Vaccination is a key public health intervention that can reduce excess mortality in humanitarian contexts. Vaccine hesitancy is thought to be a significant problem requiring demand side interventions. Participatory Learning and Action (PLA) approaches have proven effective in reducing perinatal mortality in low income settings and we aimed to apply an adapted approach in Somalia. METHODS: A randomised cluster trial was implemented in camps for internally displaced people near Mogadishu, from June to October 2021...
March 9, 2023: Vaccine
https://read.qxmd.com/read/36906406/characterization-of-flu-mosaic-nanoparticle-vaccine-candidate-using-high-performance-size-exclusion-chromatography-to-support-vaccine-process-development
#19
JOURNAL ARTICLE
Rong Sylvie Yang, Yanhong Yang, Daniel B Gowetski, Yaroslav Tsybovsky, Jason G D Gall, Q Paula Lei
This report describes an application of analytical high performance size exclusion chromatography with UV and Fluorescent detection (HPSEC-UV/FLR) method that enabled a bridging from research vaccine candidate discovery (His-tagged model) to clinical product development (Non-His-tagged molecules). HPSEC measurement can accurately determine the total trimer-to-pentamer molar ratio by either titration evaluation during the nanoparticle being assembled or dissociation during a well-formed nanoparticle being dis-assembled...
March 9, 2023: Vaccine
https://read.qxmd.com/read/36906405/lessons-from-the-bolivian-vaccine-mandate
#20
LETTER
Diana Reyna Zeballos Rivas, Juan P Aguilar Ticona, Simon Doss-Gollin
No abstract text is available yet for this article.
March 9, 2023: Vaccine
journal
journal
28816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.